CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Series A Preferred Stock [Member] Preferred Stock [Member]	Series B Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid in Capital Stock Options / Warrants [Member]	Retained Earnings [Member]	Additional Paid in Capital Preferred Stock [Member]	Total
Balance at Sep. 30, 2018	$ 50	$ 0	$ 33,311,674	$ 5,335,398	$ 3,811,700	$ (47,096,505)	$ 0	$ (4,637,683)
Balance (in Shares) at Sep. 30, 2018	5,000	0	1,468,107
Common stock issued upon conversion of debt and accrued interest			$ 57,750					57,750
Common stock issued upon conversion of debt and accrued interest (in Shares)			133,781
Net income (loss)						2,343,982		2,343,982
Balance at Sep. 30, 2019	$ 50	$ 0	$ 33,369,424	5,335,398	3,811,700	(44,752,523)	0	(2,235,951)
Balance (in Shares) at Sep. 30, 2019	5,000	0	1,601,888
Stock compensation cost, purchase warrants					399,260			399,260
Paid in Capital for StemVax Acquisition				6,375,000				6,375,000
Deemed Dividend						(6,426,348)		(6,426,348)
Preferred Stock Conversion	$ (50)	$ 250					5,088,324	5,088,524
Preferred Stock Conversion (in Shares)	(5,000)	25,000
Rounding Shares issued due to stock split (in Shares)			1,604
Net income (loss)						(6,770,215)		(6,770,215)
Balance at Sep. 30, 2020	$ 0	$ 250	$ 33,369,424	$ 11,710,398	$ 4,210,960	$ (57,949,086)	$ 5,088,324	$ (3,569,730)
Balance (in Shares) at Sep. 30, 2020	0	25,000	1,603,492